

KEYPAD Trial News

www.anzup.org.au

KEYPAD Recruitment Update – March 2022

****15 TO GO****

The Trial Management Committee has recently met and made the decision to set an end date to recruitment for the KEYPAD trial. **The last date of recruitment will be 30th June 2022** and we're asking all our KEYPAD investigators and trials teams to help us come as close to the target as possible over the next couple of months. Currently, 55 participants are enrolled and we're aware of a couple of potential patients across different sites who may be interested and eligible to join the study. Please consider prioritising the KEYPAD discussions and screening in your MDT meetings and across your networks for cross-referral opportunities.

Our team is here and ready to receive any eligibility or protocol questions so please reach out via KEYPAD.study@sydney.edu.au. Thank you for your ongoing efforts and commitment to the study and we look forward to reaching this important milestone together.

Site accrual

SITE NAME	PARTICIPANTS TO DATE
Calvary Mater Newcastle	11
Eastern Health / Box Hill	1
Flinders Medical Centre	3
Royal Brisbane & Women's Hospital	4
Northern Cancer Institute	2
Sunshine Coast University Hospital	5
Fiona Stanley Hospital	4
Concord Repatriation General Hospital	8
Monash Health (Monash Medical Centre Clayton)	2
Peter MacCallum Cancer Centre (closed)	1
Icon Cancer Care	1
St George Hospital	8
Ballarat	2
Border Medical Oncology	1
Townsville	2
St Vincent's Hospital Sydney	0
TOTAL	55

What is KEYPAD?

Denosumab and Pembrolizumab in clear cell renal carcinoma: a phase II trial.

STUDY CHAIR

**A/Professor
Craig Gedy**



Patient Wallet Cards

You may have recently received or will be receiving printed hard copies of the new Patient Wallet Cards in the mail. Please ensure your RGO approval is received and filed before completing and handing out wallet cards to your current and future KEYPAD patients.

Reminder

Please record and forward any COVID-19 protocol deviations and refer to the COVID-19 guidance document for more information.

KEYPAD is a collaboration between ANZUP and NHMRC Clinical Trials Centre.



This investigator initiated ANZUP study has been supported both financially and with study drug by MSD and Amgen.



MSD



ANZUP is supported by the Australian Government through Cancer Australia.



Australian Government
Cancer Australia



**"NO LONGER
ON MUTE"**

**ANZUP ANNUAL
SCIENTIFIC MEETING**
10-12 JULY 2022
REGISTRATIONS & ABSTRACTS NOW OPEN!

#ANZUP22 – Registrations & Abstracts now open!

We are pleased to announce early bird registrations are now open for the

#ANZUP22 Annual Scientific Meeting (ASM) and invite you to register for this face-to-face event.

The meeting is to be held in Adelaide from 10 - 12 July 2022 at the Adelaide Convention Centre.

[Register now](#) and take advantage of the early bird rates.

Abstract submissions close: Monday 11 April 2022, 9am, AEST. [Submit yours today!](#)

KEYPAD key contacts

- Clinical trial operations, CTC E: keypad.study@sydney.edu.au
- Coordinating PI: Craig Gedye E: craig.gedye@newcastle.edu.au
- Sponsor queries (payments, contracts) E: trials@anzup.org.au
- Trial pages: <https://anzup.org.au/clinical-trial/keypad/>